Oncolytic Virus

Reovirus activated NK cells show enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cells
Xing Zhao, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Suparna Dutt, Matt Coffey, Holbrook E Kohrt

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P340; DOI: 10.1186/2051-1426-3-S2-P340
Acute viral infection results in a PD-1-dependent loss of anti-tumor CD8+ T cell responses: implications for tumor immunotherapy
Frederick Kohlhapp, Erica Huelsmann, Joseph Broucek, Jason Schenkel, Howard Kaufman, Andrew Zloza

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P281; DOI: 10.1186/2051-1426-3-S2-P281
Arming the oncolytic virus enadenotucirev (EnAd) to generate enhanced locally-acting immunotherapies for cancer
Brian R Champion, Nalini Rasiah, Sam Illingworth, Hugo Calderon, Matthieu Besneux, Rochelle Lear, Darren Plumb, Prithvi Kodialbail, Alice Brown

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P334; DOI: 10.1186/2051-1426-3-S2-P334
Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
Nicola E Annels, Guy Simpson, Mehreen Arif, Mick Denyer, Attya Iqbal, David Mansfield, Sarbjinder Sandhu, Alan Melcher, Kevin Harrington, Gough Au, Mark Grose, Darren Shafren, Hugh Mostafid, Hardev Pandha

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P331; DOI: 10.1186/2051-1426-3-S2-P331
Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses
Kristian Taipale, Ilkka Liikanen, Anniina Koski, Anna Kanerva, Minna Oksanen, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P344; DOI: 10.1186/2051-1426-3-S2-P344
Potentiation of anti-glioma immunity induced by oncolytic adenovirus Delta-24-RGD through viral expression of immune co-stimulator OX40 ligand
Hong Jiang, Karen Dwyer, Laura Bover, Frederick Lang, Candelaria Gomez-Manzano, Juan Fueyo

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P337; DOI: 10.1186/2051-1426-3-S2-P337
Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
Riikka Havunen, Mikko Siurala, Suvi Parviainen, Simona Bramante, Dipongor Saha, Siri Tähtinen, Markus Vähä-Koskela, Michael Behr, Dirk Nettelbeck, Anja Ehrhardt, Akseli Hemminki

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P41; DOI: 10.1186/2051-1426-3-S2-P41
"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours
Brian R Champion, Prithvi Kodialbail, Sam Illingworth, Nalini Rasiah, Dan Cochrane, John Beadle, Kerry Fisher, Alice CN Brown

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P46; DOI: 10.1186/2051-1426-2-S3-P46
Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
Dmitriy Zamarin, Rikke B Holmgaard, Tamar Plitt, James Allison, Taha Merghoub, Jedd D Wolchok

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P132; DOI: 10.1186/2051-1426-2-S3-P132
Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
Boris Minev, Holbrook Kohrt, Mehmet Kilinc, Nanhai Chen, Audrey Feng, Maysam Pessian, Ulrike Geissinger, Erik Haefner, Desislava Tsoneva, Kliment Bozhilov, Idit Sagiv-Barfi, Xing Zhao, Narendiran Rajesekaran, Ronald Levy, Aladar Szalay

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P112; DOI: 10.1186/2051-1426-2-S3-P112

Main menu

Oncolytic Virus

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic Virus

Pages